Capricor Therapeutics
CAPRCapricor Therapeutics is a biotechnology company focused on developing and commercializing cell and exosome-based therapeutics for rare genetic disorders and diseases with high unmet medical needs.
Earnings
Next report
Aug 11, 2026 (In 4 weeks)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Capricor Therapeutics is a biotechnology company focused on developing and commercializing cell and exosome-based therapeutics for rare genetic disorders and diseases with high unmet medical needs. Its primary focus is the treatment of Duchenne muscular dystrophy (DMD), utilizing a proprietary platform of cardiosphere-derived cells (CDCs) to address progressive muscle degeneration and cardiac complications. The company also leverages its StealthX exosome platform to develop next-generation vaccines and therapeutics for infectious and monogenic diseases.
A clinical-stage leader in CDC-based therapies for DMD, currently undergoing BLA review for its lead candidate.
Questions, answered.
- What is Capricor Therapeutics's market cap?
- Capricor Therapeutics (CAPR) has a market capitalization of $1.3B and trades on NASDAQ.
- Who are Capricor Therapeutics's competitors?
- Capricor Therapeutics's key competitors include PTC Therapeutics, Inc., Sarepta Therapeutics, Inc., Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does Capricor Therapeutics partner with?
- Capricor Therapeutics's notable partners include Nippon Shinyaku Co., Ltd., National Institutes of Health, California Institute for Regenerative Medicine, and others.
- What subsidiaries does Capricor Therapeutics have?
- Capricor Therapeutics's subsidiaries include Capricor, Inc..
- Where is Capricor Therapeutics headquartered?
- Capricor Therapeutics is headquartered in United States of America and employs approximately 102 people. It has been publicly traded since 2002.